Dominari appoints Ambassador McCourt to board, withdraws $2B shelf filing

Dominari Holdings Inc. (NASDAQ: DOMH) announced the appointment of Ambassador Jamie McCourt to the Advisory Board of Dominari Securities and withdrew its previously filed $2 billion shelf registration statement.

McCourt served as United States Ambassador to France and Monaco from 2017 to 2021. She previously served as Co-Owner, President and CEO of the Los Angeles Dodgers and held a senior role at Liberty Strategic Capital. She holds degrees from Georgetown University, the Sorbonne, the University of Maryland School of Law and the MIT Sloan School of Management.

"The appointment of Ambassador McCourt represents a transformative addition to our Advisory Board," said Kyle Wool, President of Dominari Holdings and CEO of Dominari Securities. "Her extraordinary leadership experience, global perspective and proven ability to drive results in complex environments will strengthen our strategic capabilities and support the creation of long-term value for our investors."

The company withdrew its $2 billion shelf registration statement following an evaluation of current capital planning and strategic priorities. Dominari reported cash and marketable securities of $176.2 million and working capital of $198.8 million as of September 30, 2025.

"The decision to withdraw the $2 billion shelf registration underscores our confidence in Dominari's financial strength and strategic direction," said Anthony Hayes, Chief Executive Officer of Dominari Holdings. "We are fully equipped to execute on our growth initiatives, seize market opportunities and deliver exceptional long-term value to our shareholders without the need for additional capital at this time."

Dominari Holdings operates through subsidiaries engaged in wealth management, investment banking, sales and trading, and asset management. The company also seeks opportunities in AI and data center sectors.

You May Also Be Interested In

• DBV Technologies refreshes ATM program with $150M ADS offering
• Powerus subsidiary advances to Phase 3 of U.S. Army xTech competition
• Richard Lowenthal resigns from ARS Pharmaceuticals board